Avastin Sales Data
| Rank 16 |
Current sales rank, all
U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Avastin U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range |
Sales Rank |
Sales ($000) |
|
Units (000) |
|
| Q1 2013 |
16 |
$640,823 |
1.04% |
462 |
 |
| Q4 2012 |
16 |
$634,201 |
-2.49% |
462 |
-2.12% |
| Q3 2012 |
16 ( 2) |
$650,363 |
0.41% |
472 |
-0.84% |
| Q2 2012 |
18 (2) |
$647,721 |
2.46% |
476 |
3.48% |
| Q1 2012 |
20 (1) |
$632,183 |
-1.92% |
460 |
-2.13% |
| Q4 2011 |
21 |
$644,570 |
2.86% |
470 |
3.52% |
| Q3 2011 |
21 |
$626,618 |
-3.57% |
454 |
-3.61% |
| Q2 2011 |
21 |
$649,802 |
-1.29% |
471 |
-0.63% |
| Q1 2011 |
21 |
$658,284 |
|
474 |
|
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|
| March 20, 2013 | Avastin Unit Dose Syringes by Clinical Specialties: Recall - Potential For Serious Eye Infection |
| February 29, 2012 | Health Highlights: Feb. 29, 2012 |
| February 17, 2012 | US Industry Bickers Over How to Capture Fake Drugs |
| December 28, 2011 | Avastin May Help Some With Ovarian Cancer: Studies |
| December 7, 2011 | Avastin Boosted Survival for Type of Aggressive Breast Cancer: Study |
| July 1, 2011 | Avastin Rejection Supported by Cancer Experts |
| June 29, 2011 | Genentech Provides Update from FDA Hearing on Avastin for Metastatic Breast Cancer |
| June 29, 2011 | FDA Panel Rejects Avastin for Breast Cancer |
| June 28, 2011 | FDA to Hear Appeal on Breast Cancer Drug |
| June 9, 2011 | Chemo for Late-Stage Cancer Patients May Be Unjustified |
| June 4, 2011 | Cancer Drug Avastin Makes Inroads Against Ovarian Tumors |
| February 1, 2011 | More Evidence Cancer Drug Avastin May Cause Harm |
| January 4, 2011 | More Evidence Links Avastin to Heart Failure in Breast Cancer Patients |
| December 16, 2010 | FDA Advises Against Avastin as Treatment for Breast Cancer |
| December 16, 2010 | FDA Begins Process to Remove Breast Cancer Indication from Avastin Label |
| December 16, 2010 | Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States |
| July 20, 2010 | US Panel: Study Showed No Benefit With Avastin |
| July 20, 2010 | FDA Advisers Say Avastin Shouldn't Be Used for Breast Cancer |
| July 20, 2010 | Avastin Largely Safe for Patients With Type of Advanced Lung Cancer |
| March 12, 2010 | Genentech Says Avastin Trial Did Not Meet Goal |
| December 1, 2009 | CT Scan May Predict Colon Cancer Survival |
| August 5, 2009 | Scientists Learn How Cancer Drugs Cause Hypertension |
| August 4, 2009 | FDA Approves Avastin for Most Common Kidney Cancer |
| July 30, 2009 | Brain Scan May Help Predict Cancer Drug Response |
| May 30, 2009 | Drug Combo Proves Powerful Against Lung Cancer |
| May 30, 2009 | Avastin Shows No Benefit Against Early Stage Colon Cancer |
| May 25, 2009 | Cancer Drug May Boost Risk of Gastrointestinal Perforation |
| May 7, 2009 | Avastin Gets New Approval for Brain Cancer |
| March 31, 2009 | FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma) |
| November 18, 2008 | Cancer Drug Ups Risk of Clots in Veins |
| July 14, 2008 | FDA MedWatch- Avastin (bevacizumab) and Sunitinib Malate- Reports
of Microangiopathic Hemolytic Anemia In Patients Treated With This
Combination |
2)